IL-33 released by alum is responsible for early cytokine production and has adjuvant properties

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Rose Ii, William A ^a   Okragly, Angela J ^a   Patel, Chetan N ^a   Benschop, Robert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM DERIVATIVE; AUTOANTIBODY; CYTOKINE; IL33 PROTEIN, MOUSE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 33;

ANIMAL; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; KNOCKOUT MOUSE; MOUSE; NECROSIS; PATHOLOGY; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; AUTOANTIBODIES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERLEUKIN-33; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NECROSIS; SPLEEN;

EID: 84939499267     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13146     Document Type: Article

References (42)

1. Marrack, P., McKee, A. S., Munks, M. W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9, 287-293 (2009).
2. Coffman, R. L., Sher, A., Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492-503 (2010).
3. Glenny, A. T., Pope, C. G., Waddington, H., Wallace, U. Immunological notes. XVII-XXIV. The Journal of Pathology and Bacteriology 29, 31-40 (1926).
4. Park, W. H., Schroder, M. C. Diphtheria Toxin-Antitoxin and Toxoid: A Comparison. Am. J. Public Health Nations Health 22, 7-16 (1932).
5. Oleszycka, E., Lavelle, E. C. Immunomodulatory properties of the vaccine adjuvant alum. Curr. Opin. Immunol. 28, 1-5 (2014).
6. Munks, M. W. et al. Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo. Blood 116, 5191-5199 (2010).
7. Hutchison, S. et al. Antigen depot is not required for alum adjuvanticity. FASEB J. 26, 1272-1279 (2012).
8. Grun, J. L., Maurer, P. H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell. Immunol. 121, 134-145 (1989).
9. Brewer, J. M. et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4-or IL-13-mediated signaling. J. Immunol. 163, 6448-6454 (1999).
10. McKee, A. S. et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol. 183, 4403-4414 (2009).
11. Cain, D. W., Sanders, S. E., Cunningham, M. M., Kelsoe, G. Disparate adjuvant properties among three formulations of "alum". Vaccine 31, 653-660 (2013).
12. Jordan, M. B., Mills, D. M., Kappler, J., Marrack, P., Cambier, J. C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304, 1808-1810 (2004).
13. Lu, F., Hogenesch, H. Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant. Vaccine 31, 3979-3986 (2013).
14. Goto, N. et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15, 1364-1371 (1997).
15. Eisenbarth, S. C., Colegio, O. R., O'Connor, W., Sutterwala, F. S., Flavell, R. A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126 (2008).
16. Kool, M. et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205, 869-882 (2008).
17. Kool, M. et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181, 3755-3759 (2008).
18. Li, H., Willingham, S. B., Ting, J. P., Re, F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181, 17-21 (2008).
19. Marichal, T. et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat. Med. 17, 996-1002 (2011).
20. McKee, A. S. et al. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc. Natl. Acad. Sci. 110, E1122-1131 (2013).
21. Liew, F. Y., Pitman, N. I., McInnes, I. B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103-110 (2010).
22. Cayrol, C., Girard, J. P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr. Opin. Immunol. 31C, 31-37 (2014).
23. Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490 (2005).
24. Moussion, C., Ortega, N., Girard, J. P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 3, e3331 (2008).
25. Carriere, V. et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. 104, 282-287 (2007).
26. Roussel, L., Erard, M., Cayrol, C., Girard, J. P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 9, 1006-1012 (2008).
27. Lefrancais, E. et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc. Natl. Acad. Sci. 109, 1673-1678 (2012).
28. Lefrancais, E. et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc. Natl. Acad. Sci. 111, 15502-15507 (2014).
29. Talabot-Ayer, D., Lamacchia, C., Gabay, C., Palmer, G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J. Biol. Chem. 284, 19420-19426 (2009).
30. Wynn, T. A. IL-13 effector functions. Annu. Rev. Immunol. 21, 425-456 (2003).
31. Foster, P. S., Hogan, S. P., Ramsay, A. J., Matthaei, K. I., Young, I. G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 183, 195-201 (1996).
32. McKenzie, G. J. et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 9, 423-432 (1998).
33. Gavin, A. L. et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314, 1936-1938 (2006).
34. Kayamuro, H. et al. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J. Virol. 84, 12703-12712 (2010).
35. El Ridi, R., Tallima, H. Vaccine-induced protection against murine schistosomiasis mansoni with larval excretory-secretory antigens and papain or type-2 cytokines. J. Parasitol. 99, 194-202 (2013).
36. Villarreal, D. O. et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 74, 1789-1800 (2014).
37. Gao, K. et al. Transgenic expression of IL-33 activates CD8(+ ) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 335, 463-471 (2013).
38. Yang, Q. et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur. J. Immunol. 41, 3351-3360 (2011).
39. Bonilla, W. V. et al. The alarmin interleukin-33 drives protective antiviral CD8(+ ) T cell responses. Science 335, 984-989 (2012).
40. Kurowska-Stolarska, M. et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181, 4780-4790 (2008).
41. Rank, M. A. et al. IL-33-activated dendritic cells induce an atypical TH2-type response. J. Allergy Clin. Immunol. 123, 1047-1054 (2009).
42. Besnard, A. G. et al. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur. J. Immunol. 41, 1675-1686 (2011).